Five things for pharma marketers to know: Thursday, March 2, 2017

Share this content:

1. Ten drugmakers, including Pfizer, Merck, and Johnson & Johnson, petitioned the Securities and Exchange Commission to exclude drug pricing transparency proposals from their proxy ballots, in response to investor demands that they disclose more information about price increases. (WSJ)

2. At least 83% of 104 patient advocacy groups in the U.S. accept funding from pharmaceutical, medical device, and biotech companies, and many do not report the contributions, new research found. (Kaiser Health News)

3. Juno Therapeutics halted development of its experimental CAR-T treatment after it reported five patients participating in a clinical trial died in 2016. (Stat)

4. Jakob Riis, Novo Nordisk's head of North American operations, resigned and will be replaced by Doug Langa, currently SVP for market access. Riis had been in that role since September. (Reuters)

5. Pfizer filed a lawsuit against a former global marketing director for misappropriating company information. The drugmaker said she forwarded information such as strategic and operating plans and product launch roadmaps to her personal email account. (Stat)

Share this content:
Scroll down to see the next article